Brief: China Biotech Services Says Shanghai Longyao Received Approval For Clinical Trial For Product LY007 Cellular Injection
22/01/2021 24:52
Jan 22 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* SHANGHAI LONGYAO RECEIVED APPROVAL FOR CLINICAL TRIAL FOR
PRODUCT LY007 CELLULAR INJECTION FROM NMPA
Source text for Eikon: ID:nHKS3drzbs
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)